We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Onconetix Inc (ONCO) USD0.00001

Sell:$5.73 Buy:$5.96 Change: $0.79 (15.34%)
Market closed |  Prices as at close on 11 October 2024 | Switch to live prices |
Sell:$5.73
Buy:$5.96
Change: $0.79 (15.34%)
Market closed |  Prices as at close on 11 October 2024 | Switch to live prices |
Sell:$5.73
Buy:$5.96
Change: $0.79 (15.34%)
Market closed |  Prices as at close on 11 October 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

Contact details

Address:
201 E. Fifth Street, Suite 1900
CINCINNATI
45202
United States
Telephone:
+1 (513) 6204101
Website:
https://onconetix.gcs-web.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ONCO
ISIN:
US68237Q1040
Market cap:
$49.35 million
Shares in issue:
8.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ralph Schiess
    Interim Chief Executive Officer, Chief Science Officer
  • Karina Fedasz
    Interim Chief Financial Officer
  • Christian Bruehlmann
    Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.